Seattle Children's and Benaroya Research Institutes Receive $1M Grant to Find Type 1 Diabetes Treatment

Seattle Children's and Benaroya Research Institutes Receive $1M Grant to Find Type 1 Diabetes Treatment

Seattle Children’s Research Institute has received a $1 million grant to study fighting type 1 diabetes with a person’s own T-cells, freeing people from having to take insulin their whole life. “This is a very active area that people are excited about,” said Dr. David Rawlings, director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. “We’ve been very successful in the last few years in editing T-cells, so we are confident we will be able to find a way to do this effectively.”

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation’s top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children’s bold initiative – It Starts With Yes: The Campaign for Seattle Children’s – to transform children’s health for generations to come.

For more information, visit or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.